Crystalys Therapeutics
PrivateLast Round
Series A
Sep 30, 2025
Est. Valuation
$280M
Total Funding Raised
$228M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Crystalys Therapeutics is a clinical-stage biopharmaceutical company developing dotinurad, a next-generation URAT1 inhibitor, as a second-line therapy for gout.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Crystalys Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Crystalys Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Sep 30, 2025 |
Key People
Founding team and executive leadership
Crystalys Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Conrad Prebys Foundation | Series A |
| Wedbush Healthcare Partners | Series A |
| Perceptive Advisors | Series A |
| KB Investment | Series A |
| Lightstone Ventures | Series A |
| abrdn Inc. | Series A |
| Pontifax Venture Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 14, 2026
Grew 45% QoQ, from 11 to 16 employees.
- Feb 13, 2026
Grew 50% QoQ, from 10 to 15 employees.
Crystalys Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Crystalys Therapeutics's valuation, stock price, and market status.